The panelists summarize their approaches to choosing frontline treatment for advanced clear cell RCC, balancing long-term and short-term efficacy data on IO-IO versus IO-TKI regimens based on recent study results.
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC
No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.
Managing AEs with Gemcitabine Intravesical System in NMIBC
Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.